Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberWO1995002357 A1
Publication typeApplication
Application numberPCT/US1994/006684
Publication date26 Jan 1995
Filing date14 Jun 1994
Priority date16 Jul 1993
Also published asCA2167393A1, EP0708615A1, EP0708615A4
Publication numberPCT/1994/6684, PCT/US/1994/006684, PCT/US/1994/06684, PCT/US/94/006684, PCT/US/94/06684, PCT/US1994/006684, PCT/US1994/06684, PCT/US1994006684, PCT/US199406684, PCT/US94/006684, PCT/US94/06684, PCT/US94006684, PCT/US9406684, WO 1995/002357 A1, WO 1995002357 A1, WO 1995002357A1, WO 9502357 A1, WO 9502357A1, WO-A1-1995002357, WO-A1-9502357, WO1995/002357A1, WO1995002357 A1, WO1995002357A1, WO9502357 A1, WO9502357A1
InventorsNooshin T. Azimi
ApplicantCygnus Therapeutic Systems
Export CitationBiBTeX, EndNote, RefMan
External Links: Patentscope, Espacenet
Noninvasive glucose monitor
WO 1995002357 A1
Abstract
This invention is a noninvasive glucose monitoring apparatus and method that does not rely upon heat, electricity or chemicals to collect glucose from interstitial fluid across the patient's skin. Moreover, the method and apparatus monitor blood glucose in real time, i.e., in a time period short enough to enable a diabetic to take appropriate action to correct blood glucose levels. A collection device (10) comprising a reservoir (12) containing a glucose collection medium such as water is placed against the stratum corneum of the patient's skin for a predetermined period of time. At least a portion of the glucose collection medium is removed from the reservoir at the end of the predetermined time and analyzed for glucose concentration.
Claims  (OCR text may contain errors)
What is claimed is:
1. A noninvasive method of monitoring blood glucose across the skin of a patient without the use of a sweat inducer or a permeability enhancer, the method comprising the following steps: placing a reservoir of a glucose collection medium adjacent the patient's skin; and analyzing the glucose collection medium to measure the amount of glucose collected.
2. The method of claim 1 wherein the glucose collecting medium comprises water.
3. The method of claim l wherein the reservoir has an open side facing the patient's skin so that the glucose collection medium is in direct contact with the patient's skin.
4. The method of claim 1 wherein the reservoir comprises a glucose transfer membrane disposed between the glucose collection medium and the patient's skin.
5. The method of claim 1 wherein the . analyzing step comprises pulsed amperometric detection.
6. The method of claim 1 wherein the analyzing step is performed at the end of a predetermined time period in the range of 5 to 10 minutes.
7. The method of claim 6 wherein the glucose collecting medium consists essentially of water.
8. The method of claim 7 further comprising the step of removing the glucose collection medium from the reservoir before the analyzing step.
9. The method of claim 8 wherein the analyzing step comprises pulsed amperometric detection.
10. The method of claim 1 wherein the analyzing step comprises exposing an glucose-responsive enzyme to the glucose collection medium, the enzyme being in contact with an indicating electrode.
11. A noninvasive method of collecting glucose from a patient across the skin of a patient without the use of a sweat inducer or a permeability enhancer, the method comprising the steps of placing a reservoir of a glucose collection medium adjacent the patient's skin for a period of time and removing at least a portion of the glucose collection medium from the reservoir.
12. A noninvasive method of collecting glucose from a patient across the skin of a patient without the use of a sweat inducer or a permeability enhancer, the method comprising the steps of placing a reservoir of a glucose collection medium adjacent the patient's skin and exposing a glucose-responsive enzyme to the glucose collection medium, the glucose-responsive enzyme being in contact with an indicating electrode.
13. A glucose collection device comprising: a reservoir containing a glucose collection medium for collecting glucose from a patient in real time without the use of a permeability enhancer or a sweat inducer; and means for attaching the device to a patient so that glucose can travel across the patient's skin.
14. The device of claim 13 wherein the glucose collection medium comprises water.
15. The device of claim 13 wherein the means for attaching comprises adhesive.
16. The device of claim 13 further comprising means for extracting the glucose collection medium from the reservoir without detaching the device from the patient.
17. A glucose monitoring system comprising: a glucose collection device comprising a reservoir containing a glucose collection medium for collecting glucose from a patient in real time without the use of a permeability enhancer or a sweat inducer and means for attaching the device to a patient so that glucose can travel across the patient's skin; and means for measuring the concentration of glucose within the glucose collection medium.
18. The glucose monitoring system of claim 17 wherein the means for measuring comprises a glucose- responsive enzyme in contact with the glucose collection medium, an indicating electrode in contact with the enzyme, a reference electrode in contact with the patient's skin, and an instrument in electrical contact with the indicating electrode and the reference electrode.
Description  (OCR text may contain errors)

NONINVASIVE GLUCOSE MONITOR

Background of the Invention

This invention relates generally to methods and apparatus for glucose collection and concentration measurement. In particular, the invention is directed to a method and apparatus for monitoring blood glucose levels noninvasively through a patient's skin.

People suffering from diabetes mellitus must monitor blood glucose levels over the course of the day. The most common prior art method of measuring blood glucose levels is by actually drawing a portion of the subject's blood and performing a chemical analysis on the sample. Continually drawing blood creates safety risks for the patient, however. The prior art has described "noninvasive" methods for measuring blood glucose levels. These supposedly noninvasive methods actually involve the application of chemicals, electricity, heat, or negative pressure to draw out body fluids other than blood that may nonetheless contain levels of glucose that correlate with blood glucose levels. For example, U.S. Patent No. 5,161,532 describes a glucose sensor that uses a pump to draw interstitial fluid out through the patient's skin into a sensor. The '532 patent states that any glucose in the interstitial fluid reacts with a chemical within the sensor to produce an electrical signal that is detected by a pair of electrodes.

U.S. Patent No. 5,036,861 describes a glucose monitor that collects the patient's sweat through a skin patch attached to the patient's wrist. Iontophoresis is used to transdermally introduce a gel into the patient's skin. The gel contains a cholinergic agent for stimulating the secretion mechanism of the eccrine sweat gland and agents that minimize or prevent loss of glucose from the sweat as it travels from the sweat gland to the skin patch. As in the '532 patent, the device described in the '861 patent measures the glucose level in the collected sweat using electrodes.

U.S. Patent No. 5,139,023 describes yet another "noninvasive" apparatus and method for monitoring blood glucose. The monitor includes a glucose receiving medium such as water enclosed in a housing that holds the receiving medium against the patient's epithelial membrane. The glucose receiving medium includes a permeation enhancing chemical such as a natural bile salt that enhances glucose permeability from interstitial fluid across the epithelial membrane into the monitor. An attempt to collect glucose according to the '023 method and apparatus but without any permeation enhancing agent failed to show that any glucose was collected.

Finally, published European Patent Application EP 0 304 304 discloses a transdermal glucose detection system in which the detector contains a porous carrier saturated with detector chemicals. The detector adhesively attaches to the patient's skin. A membrane serves as a barrier to prevent migration of the detector chemicals out of the detector while permitting glucose to migrate into the detector. Interaction between glucose and the detector chemicals causes a perceivable color change over a six to twelve hour period. The device only detects the presence of glucose; it does not measure the actual amount of glucose in the detector. Summary of the Invention

This invention provides a truly noninvasive glucose monitoring apparatus and method that does not rely upon heat, electricity or chemicals to collect glucose from interstitial fluid across the patient's skin. Moreover, the method and apparatus of this invention monitor blood glucose in real time, that is to say, in a time period short enough to enable a diabetic to take appropriate action to correct blood glucose levels.

In a preferred embodiment, a collection device comprising a reservoir containing a glucose collection medium such as water is placed against the stratum corneum of the patient's skin for a predetermined period of time. At least a portion of the glucose collection medium is removed from the reservoir at the end of the predetermined time and analyzed for glucose concentration.

Brief Description of the Drawings

Figure 1 is a side cross-sectional view of a glucose collection device according to the preferred embodiment of this invention.

Figure 2 is a bottom elevational view of the preferred glucose collection device.

Figure 3 is a cross-sectional view of a sensor for use with a glucose analysis method for use with this invention.

Figure 4 is a schematic representation of a glucose monitoring system according to this invention.

Detailed Description of the Preferred Embodiment

This invention presents a simple and noninvasive method for monitoring blood glucose levels. It is well-known that glucose can be found in a patient's interstitial fluid and in a patient's sweat. Heretofore, however, it had been thought that glucose could not cross the patient's skin in a detectable amount in real time without the use of a permeability enhancer. See, e.g., U.S. Patent No. 5,139,023 at col. 7, line 3. It had also been thought that even when sweat or interstitial fluid is actively extracted from the patient, active pharmacological agents are needed to preserve the presence of glucose in the extracted sample. See, e.g., U.S. Patent No. 5,036,861, col. 3, lines 1-10.

This invention is a method and apparatus for detecting blood glucose in a truly noninvasive manner without actively extracting interstitial fluid from the patient and without the use of sweat inducers, glucose preservers or permeability enhancers. In a preferred embodiment, glucose is collected through the stratum corneum of the patient's skin by a reservoir containing a glucose collection medium. After the passage of a predetermined time period, the glucose collection medium is analyzed to measure the quantity of glucose present. A preferred collection device for practicing this invention is shown in Figures 1 and 2. The device 10 comprises a reservoir 12 bordered by a cover 14, adhesive layer 16, and the stratum corneum of the patient's skin 18. As shown in part in Figure 2, the device is formed by attaching the plastic cover 14 to a double-sided adhesive 16 in which an oval or other-shaped hole has been formed. In the preferred embodiment, cover 14 is formed from cellophane plastic and adhesive layer 16 is Avery double-sided adhesive, part no. MED 3044.

The preferred glucose collection medium is distilled deionized water. According to the preferred method, the distilled deionized water is injected into reservoir 12 through a hypodermic needle and syringe 20. Despite suggestions to the contrary in the prior art, glucose will migrate from the patient's interstitial fluid through the skin 18 and into the water within reservoir 12. After the water has rested against the patient's skin for a predetermined period of time, the water is withdrawn for analysis. This glucose collection device and method can collect glucose from the patient without the use of chemicals or mechanical extraction.

Alternatively, a hydrogel may be used as a collection medium. Suitable hydrogels are described in U.S. Patent No. 5,139,023.

Water (or other collection medium) from the reservoir may be extracted at periodic intervals (preferably in the range of 5 to 10 minutes) and analyzed to determine its glucose content. A preferred glucose analysis method is described by LaCourse et al. in "Optimization of Waveforms for Pulsed Amperometric Detection of Carbohydrates Based on Pulsed Voltammetry, " 65 Analytical Chemistry 50-55 (1 January 1993) , although other analysis methods may be used. The preferred pulse amperometric voltammetry (PAD) analysis method combines high performance liquid chromatography with electrochemical detection using bi-directional voltage waveforms. Specifically, water extracted from the reservoir is diffused onto a chromatography column. The column is washed with a high pressure solvent such as a NaOH solution. A stepped voltage waveform is applied across two electrodes in the solution, one of which is a gold rotating disk electrode. The voltage waveform has three parts: a detection potential in the range of -200 to +400 mV for greater than 40 ms detection period, an oxidation potential in the range of 300 to 800 mV for greater than approximately 60 ms, and a reduction potential in the range of -800 to +100 mV for greater than approximately 60 ms. A plot of electrode current at the gold electrode versus applied voltage yields a curve with signature peaks at specific voltage values for certain solutes such as glucose. The peak amplitude or peak area are measures of the concentration of that solute. An alternative glucose concentration analysis method is shown schematically in Figures 3 and 4. The glucose measurement technique of this embodiment is similar to the enzymatic technique described in U.S. Patent No. 5,165,407 and does not require the glucose collection medium to be extracted from the collection device.

A glucose sensor 30 is shown in detail in Figure 3. A sensor body 32 is received within a stainless steel hollow tubular needle 34. The sensor body includes a Teflon-coated platinum-iridium wire 36

(90% Pt/10% Ir) having a total O.D. of about 0.2 mm and a cavity 38 formed therein. Cavity 38 is approximately 1.0 mm in length and is located about 3.0 mm from the distal tip of the wire 36. A glucose oxidase layer 40 is immobilized within the cavity 38, and comprises a cellulose acetate polymer layer attached to the surface of the Pt-Ir wire, with glucose oxidase crosslinked through glutaraldehyde onto the cellulose acetate to form an indicating electrode. The procedure is described in more detail in U.S. Patent No. 5,165,407. The entirety of the indicating electrode is covered by a membrane 42 of polyurethane, also as described in U.S. Patent No. 5,165,407, to control the diffusion rate of glucose onto the indicating electrode. Needle 34 has an aperture 44 adjacent its sharpened distal end 46 to expose layer 40. A silicone rubber plug 48 closes one end of the needle and a bead of epoxy 50 closes the other end, as shown. A plastic sheet 52 surrounding the proximal end of the needle serves as a holder. Figure 4 is a schematic representation of a glucose collection and measurement system using this alternative glucose analysis method. The sensor 30 described above with reference to Figure 3 is inserted into a glucose collection device attached to the patient's skin 18 as described with reference to Figures 1 and 2 above so that the sensor's aperture 44 is exposed to the glucose collection medium 12. A conductor 60 leads from the indicating electrode of sensor 30 to a glucose measurement instrument 62. A second conductor 64 leads from a reference electrode 66 attached to the patient's skin 18. Instrument 62 applies a voltage across conductors 60 and 64; the current measured across the electrodes is related to the concentration of glucose in the collection medium in a manner known in the art.

The invention may be further explained through the following examples. The examples are not intended as a limitation to any claimed embodiment.

Examples 1-5

Glucose was collected from an adult human using an apparatus substantially similar to the apparatus shown in Figures 1 and 2. The device was attached to the stratum corneum of the skin on the patient's forearm, and the device's reservoir was initially filled with a sample consisting of 0.5 ml. of distilled deionized water via a hypodermic needle and syringe. The sample was withdrawn from the reservoir after five minutes and was replaced with a fresh sample of distilled deionized water at five minute intervals for a total of 30 minutes. The final sample remained in the reservoir for 30 minutes before being withdrawn and analyzed.

The withdrawn samples were analyzed using pulsed amperometric voltammetry. The results are shown in Table I, with the glucose concentrations expressed in micromoles.

TABLE I

Sample 1 2 3 4 5

0-5 min 3.13μM 2.86 M 6.lOμM 9.24μM 1.66/iM

5-10 min 1.74 " 1.42 " 3.80 " 4.07 " 1.05 "

10-15 min 1.08 " 0.85 " 2.53 " 2.90 " 0.83 "

15-20 min 1.44 " 0.88 " 1.67 " 2.24 " 0.56 "

20-25 min 1.13 " 0.46 " 1.48 " 2.57 " 0.70 "

25-30 min 0.77 " 0.56 " 1.15 " 3.07 " 1.09 "

30-60 min 1.91 " 1.46 " 3.35 " 13.5 " 1.20 "

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US5056521 *29 Jun 198915 Oct 1991Health Craft International, Inc.Method for monitoring glucose level
US5076273 *13 Nov 199031 Dec 1991Sudor PartnersMethod and apparatus for determination of chemical species in body fluid
US5139023 *2 Jun 198918 Aug 1992Theratech Inc.Apparatus and method for noninvasive blood glucose monitoring
Non-Patent Citations
Reference
1 *See also references of EP0708615A4
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
WO1998004190A3 *30 Jul 199725 Jun 1998Dtr Dermal Therapy IncMethod and apparatus for non-invasive determination of glucose in body fluids
WO2010052849A127 Oct 200914 May 2010Panasonic CorporationMeasurement device, insulin infusion device, measurement method, method for controlling insulin infusion device, and program
EP2255724A120 May 20101 Dec 2010Sysmex CorporationMethod for analyzing analyte in tissue fluid, analyzer for analyzing analyte in tissue fluid, cartridge for analyzing analyte in tissue fluid, and kit for analyzing analyte in tissue fluid
EP2329771A3 *13 Jul 200522 Jun 2011DexCom, Inc.Transcutaneous analyte sensor
EP2998731A1 *6 Nov 201423 Mar 2016i-Sens, Inc.Apparatus and method for measuring concentration of an analyte in whole blood samples
EP3043174A127 Oct 200913 Jul 2016Panasonic Healthcare Holdings Co., Ltd.Measurement device
US5890489 *30 Jul 19966 Apr 1999Dermal Therapy (Barbados) Inc.Method for non-invasive determination of glucose in body fluids
US5954685 *24 May 199621 Sep 1999Cygnus, Inc.Electrochemical sensor with dual purpose electrode
US6144869 *11 May 19997 Nov 2000Cygnus, Inc.Monitoring of physiological analytes
US618041630 Sep 199830 Jan 2001Cygnus, Inc.Method and device for predicting physiological values
US623347111 May 199915 May 2001Cygnus, Inc.Signal processing for measurement of physiological analysis
US62510837 Sep 199926 Jun 2001Amira MedicalInterstitial fluid methods and devices for determination of an analyte in the body
US627236411 May 19997 Aug 2001Cygnus, Inc.Method and device for predicting physiological values
US628412628 Aug 20004 Sep 2001Cygnus, Inc.Electrode with improved signal to noise ratio
US632616027 Sep 19994 Dec 2001Cygnus, Inc.Microprocessors for use in a device for predicting physiological values
US634123216 Mar 200122 Jan 2002Cygnus, Inc.Methods of producing collection assemblies, laminates, and autosensor assemblies for use in transdermal sampling systems
US635677616 Aug 200012 Mar 2002Cygnus, Inc.Device for monitoring of physiological analytes
US639164327 Oct 199921 May 2002Cygnus, Inc.Kit and method for quality control testing of an iontophoretic sampling system
US639331811 May 199921 May 2002Cygnus, Inc.Collection assemblies, laminates, and autosensor assemblies for use in transdermal sampling systems
US643841430 Nov 200120 Aug 2002Cygnus, Inc.Collection assemblies, laminates, and autosensor assemblies for use in transdermal sampling systems
US65462695 Jan 20018 Apr 2003Cygnus, Inc.Method and device for predicting physiological values
US656197811 Feb 200013 May 2003Cygnus, Inc.Devices and methods for frequent measurement of an analyte present in a biological system
US658770510 Mar 19991 Jul 2003Lynn KimBiosensor, iontophoretic sampling system, and methods of use thereof
US659451420 Dec 200115 Jul 2003Cygnus, Inc.Device for monitoring of physiological analytes
US659591927 Feb 200122 Jul 2003Cygnus, Inc.Device for signal processing for measurement of physiological analytes
US661507821 Apr 20002 Sep 2003Cygnus, Inc.Methods and devices for removing interfering species
US665309123 Jul 200125 Nov 2003Cyngnus, Inc.Method and device for predicting physiological values
US673677729 Jan 200318 May 2004Cygnus, Inc.Biosensor, iontophoretic sampling system, and methods of use thereof
US681674213 Feb 20049 Nov 2004Cygnus, Inc.Biosensor and methods of use thereof
US685079014 May 20031 Feb 2005Cygnus, Inc.Monitoring of physiological analytes
US690290514 May 20037 Jun 2005Cygnus, Inc.Glucose measuring assembly with a hydrogel
US69998108 Sep 200414 Feb 2006Animas Technologies LlcBiosensor and methods of use thereof
US715097518 Aug 200319 Dec 2006Animas Technologies, LlcHydrogel composition for measuring glucose flux
US716351129 Jan 200316 Jan 2007Animas Technologies, LlcDevices and methods for frequent measurement of an analyte present in a biological system
US71741995 Nov 20046 Feb 2007Animas Technologies, LlcMonitoring a physiological analytes
US718306817 Feb 200527 Feb 2007Animas Technologies, LlcMethods of manufacturing glucose measuring assemblies with hydrogels
US729586712 Feb 200313 Nov 2007Animas CorporationSignal processing for measurement of physiological analytes
US740505524 Jul 200329 Jul 2008Animas Technologies LlcMethod and device for predicting physiological values
US74979401 Sep 20043 Mar 2009Koji SodeGlucose sensor and glucose level measuring apparatus
US769977513 Oct 200420 Apr 2010Animas Technologies, LlcMethods for estimating analyte-related signals, microprocessors comprising programming to control performance of the methods, and analyte monitoring devices employing the methods
US787339930 Jan 200718 Jan 2011Animas CorporationMonitoring of physiological analytes
US793549930 Jun 20083 May 2011Animas CorporationMethod and device for predicting physiological values
US827763617 Feb 20092 Oct 2012Koji SodeGlucose sensor and glucose level measuring apparatus
US859757027 Oct 20093 Dec 2013Panasonic CorporationMeasurement device, insulin infusion device, measurement method, method for controlling insulin infusion device, and program
US869077511 Apr 20088 Apr 2014Dexcom, Inc.Transcutaneous analyte sensor
US874731628 Jan 201110 Jun 2014Sysmex CorporationIn vivo component measurement method, data processing method for in vivo component measurement, in vivo component measurement apparatus and collection member
US885843410 Mar 200514 Oct 2014Dexcom, Inc.Transcutaneous analyte sensor
US887081013 Sep 201228 Oct 2014Echo Therapeutics, Inc.Method and apparatus for enhancement of transdermal transport
US888627222 Feb 200611 Nov 2014Dexcom, Inc.Analyte sensor
US898983310 Mar 200524 Mar 2015Dexcom, Inc.Transcutaneous analyte sensor
US904419910 Mar 20052 Jun 2015Dexcom, Inc.Transcutaneous analyte sensor
US906074219 Mar 201023 Jun 2015Dexcom, Inc.Transcutaneous analyte sensor
US907862631 Mar 201114 Jul 2015Dexcom, Inc.Transcutaneous analyte sensor
US92479004 Jun 20132 Feb 2016Dexcom, Inc.Analyte sensor
US92479012 Aug 20062 Feb 2016Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US941477710 Mar 200516 Aug 2016Dexcom, Inc.Transcutaneous analyte sensor
US94209684 Apr 201223 Aug 2016Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US950441315 Apr 201329 Nov 2016Dexcom, Inc.Dual electrode system for a continuous analyte sensor
US95107824 Apr 20126 Dec 2016Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US957252722 Jan 201321 Feb 2017Echo Therapeutics, Inc.Skin permeation device for analyte sensing or transdermal drug delivery
US957905326 Mar 201028 Feb 2017Dexcom, Inc.Dual electrode system for a continuous analyte sensor
US95856074 Apr 20127 Mar 2017Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US960355713 May 201328 Mar 2017Dexcom, Inc.Transcutaneous analyte sensor
US961003113 Apr 20114 Apr 2017Dexcom, Inc.Transcutaneous analyte sensor
US962269017 Oct 201318 Apr 2017Panasonic Healthcare Holdings Co., Ltd.Measurement device
US966867726 Oct 20156 Jun 2017Dexcom, Inc.Analyte sensor
USRE38681 *2 Dec 20024 Jan 2005Cygnus, Inc.Electrode with improved signal to noise ratio
Classifications
International ClassificationG01N33/66, A61B5/00
Cooperative ClassificationA61B5/14532
European ClassificationA61B5/145G
Legal Events
DateCodeEventDescription
26 Jan 1995AKDesignated states
Kind code of ref document: A1
Designated state(s): AU CA FI JP KR NO NZ
26 Jan 1995ALDesignated countries for regional patents
Kind code of ref document: A1
Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
13 Apr 1995DFPERequest for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
3 May 1995121Ep: the epo has been informed by wipo that ep was designated in this application
15 Jan 1996WWEWipo information: entry into national phase
Ref document number: 1994920190
Country of ref document: EP
16 Jan 1996ENPEntry into the national phase in:
Ref country code: CA
Ref document number: 2167393
Kind code of ref document: A
Format of ref document f/p: F
16 Jan 1996WWEWipo information: entry into national phase
Ref document number: 2167393
Country of ref document: CA
1 May 1996WWPWipo information: published in national office
Ref document number: 1994920190
Country of ref document: EP
11 Dec 1998WWWWipo information: withdrawn in national office
Ref document number: 1994920190
Country of ref document: EP